Chromis Therapeutics
San Diego
About Chromis Therapeutics
Chromis Therapeutics, Inc. (Chromis) is a San Diego-based biopharmaceutical company, focused on the development of curative treatments for chronic HBV infection, based on its advanced proprietary drug design and discovery platform. The company is seeking investment to advance its novel cccDNA inhibitor (CHR101), viral entry and viral capsid assembly inhibitor lead candidates for the treatment of chronic HBV. CHR101 has a potential to eradicate HBV and to efficiently cure chronically infected HBV patients, as compared to drugs currently on the market. CHR101's activity is supported by a robust discovery preclinical data package.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 251 – 500
- Estimated revenue: Less than $1M
- Total funding: $3.0M
- Funding stage: Seed
- Last round: Seed (Feb 2016)
- Website: chromisthera.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/chromis-therapeutics-216599 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.